Pyrrolidine dithiocarbamate ameliorates rotenone-induced Parkinson’s disease in rats  by Abdelkader, Noha F. et al.
Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxxContents lists available at ScienceDirect
Bulletin of Faculty of Pharmacy, Cairo University
journal homepage: www.sciencedirect .comOriginal ArticlePyrrolidine dithiocarbamate ameliorates rotenone-induced Parkinson’s
disease in ratshttp://dx.doi.org/10.1016/j.bfopcu.2016.11.003
1110-0931/ 2016 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Peer review under responsibility of Faculty of Pharmacy, Cairo University.
⇑ Corresponding author at: Department of Pharmacology and Toxicology, Faculty
of Pharmacy, Cairo University, Kasr El-Aini St., 11562 Cairo, Egypt.
E-mail address: noha.fawzy@pharma.cu.edu.eg (N.F. Abdelkader).
Please cite this article in press as: N.F. Abdelkader et al., Pyrrolidine dithiocarbamate ameliorates rotenone-induced Parkinson’s disease in rats, B
Facult Pharmacy Cairo Univ (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.11.003Noha F. Abdelkader a,⇑, Nadia M. Arafa b, Amina S. Attia a, Afaf A. Ain-Shoka a, Dalaal M. Abdallah a
a Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
b Physiology Department, National Organization for Drug Control and Research (NODCAR), Giza, Egypta r t i c l e i n f o
Article history:
Received 21 September 2016
Accepted 16 November 2016
Available online xxxx
Keywords:
Pyrrolidine dithiocarbamate
Rotenone
Parkinson’s disease
Inflammation
Oxidative stressa b s t r a c t
Pyrrolidine dithiocarbamate (PDTC), a low-molecular-weight thiol antioxidant, possesses neuroprotec-
tion; however, its possible modulatory effect in Parkinson’s disease (PD) has not been tested. Male
Wistar rats were injected with rotenone to induce PD-like symptoms. Histopathological findings showed
that striatal neurons were degenerated following rotenone administration, an effect that was accompa-
nied by behavioral deficits. Furthermore, rotenone decreased striatal dopamine (DA) and glutamate and
prominently increased serotonin, GABA, glutathione (GSH), thiobarbituric acid reactive substances
(TBARS), and myeloperoxidase (MPO) levels. Daily treatment with PDTC protected against rotenone
induced changes at the microscopic level, decreased the extent of motor dysfunctions, and markedly
increased DA and suppressed glutamate levels. It also reduced TBARS, GSH, and MPO. Whereas, rotenone
neither affected striatal caspase-3 activity nor tumor necrosis factor-a level, PDTC treatment reduced the
later. The current study reveals the effectiveness of PDTC against rotenone-induced PD via enhancement
of DA, as well as antioxidant and anti-inflammatory properties.
 2016 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
An interplay between environmental and genetic factors exists,
where progressive loss of dopaminergic (DAergic) neurons in the
substantia nigra (SN) is the core feature of Parkinson’s disease
(PD) [1]. Human post-mortem PD brains display increased oxida-
tive damage to lipids, proteins and DNA [2]. DAergic neurons in
the SN are highly susceptible to oxidative damage due to the high
oxygen consumption of this brain region together with the low
levels of antioxidant enzymes and molecules [3]. Furthermore,
reactive oxygen species (ROS) initiate inflammatory pathways,
hence extending the deleterious milieu for vulnerable neuronal
populations [4]. Elevated levels of reactive microglia and pro-
inflammatory cytokines have been observed in SN of both patients
and experimental animal models of PD as reviewed byWhitton [5].
In PD, microglial activation outcomes the release of a wide array of
cytotoxic factors including pro-inflammatory cytokines, ROS, nitric
oxide and excitatory amino acids that impact neurons to undergo
neurodegeneration [6,7]. Moreover, activated microglia clusteraround DAergic neurons to undergo active phagocytosis [8].
Indeed, both oxidative stress and inflammation contribute to the
neuronal degeneration observed in PD [9,10].
Pyrrolidine dithiocarbamate (PDTC), a low-molecular-weight
thiol compound, is used clinically in heavy metal poisoning, as well
as treatment of fungal and bacterial infections [11]. Experimen-
tally, PDTC has been shown to protect against arthritis, liver and
brain ischemia, spinal cord injury and Alzheimer’s disease [12–
14]. PDTC augments cellular defense mechanisms through upregu-
lation of cytoprotective genes, including heat shock protein 70 and
endogenous antioxidants, such as superoxide dismutase and glu-
tathione (GSH) [15,16]. Besides, PDTC possesses metal chelating
activity, hence enhancing its antioxidant property [17]. PDTC is
also a potent inhibitor of nuclear factor-(NF)-jB that initiates the
transcription of numerous pro-inflammatory mediators, such as
tumor necrosis factor (TNF)-a [18,19].
Current therapies of PD chiefly involve DA replacement provid-
ing thus improvement of motor deficits; however, such treatments
are associated with drug-induced motor complications [20]. Since
PDTC is clinically tolerated [11] and has broad cytoprotective prop-
erties associated by both antioxidant and anti-inflammatory
effects [21–23], its use might slow progression of multifactorial
PD, aliment. Therefore, the present study was undertaken to eval-
uate the prophylactic effect of PDTC in a rat model of PD inducedulletin
2 N.F. Abdelkader et al. / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxxby rotenone, a widely used natural pesticide with potent mito-
chondrial complex-I inhibitory activity [24]. Repeated exposure
to low doses of rotenone produces nigrostriatal DAergic
neurodegeneration, accompanied by behavioral and
neurochemical/-pathological changes, which are hallmarks of
human PD [24]. The effect of PDTC was tested on motor impair-
ment, striatal monoamines, glutamate, GABA, redox status, some
inflammatory biomarkers and caspase-3, as well as histopatholog-
ical changes induced by rotenone.2. Experimental procedures
2.1. Animals
Adult male Wistar rats, weighing 250 ± 20 g, were used in the
present study. Animals were allocated in groups, maintained on a
12/12 h light dark cycle, had free access to standard chow diet
and water and were allowed to accommodate for one week in
the animal house at the Faculty of Pharmacy, Cairo University. Ani-
mal handling and experimental protocols were approved by the
Research Ethical Committee of Faculty of Pharmacy, Cairo Univer-
sity (Permit Number: PT 67) and complies with the Guide for Care
and Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85-23, revised 1996).
2.2. Rotenone-induced Parkinson’s disease, treatment, and striatal
isolation
Animals were divided into three groups (18–21 rats). Group I
animals received dimethyl sulfoxide (DMSO) and served as control.
Group II and III animals received six subcutaneous injections of
rotenone (Sigma-Aldrich, MO, USA) at a dose of 1.5 mg/kg dis-
solved in DMSO, every other day [25]. Animals in group III were
daily treated with PDTC ammonium salt (50 mg/kg, i.p.; Sigma-
Aldrich, MO, USA) [26] for a period of 11 days, one hour before
rotenone on the days of the insecticide injection. Rats in each
group were screened for motor impairment between 9:00 am
and 12:00 pm using the open field and rotarod tests, 24 h after
the last injection of rotenone. At the end of the observation period,
animals in each group were further subdivided into three sub-
groups, then euthanized; thereafter in the first set of subgroups
(n = 6–9 rats per subgroup) both straita were homogenized in
ice-cold saline for the estimation of TBARS, GSH, MPO, TNF-a,
and caspase-3. In the second set of subgroups of 8 rats, both straita,
were homogenized in 75% (v) aqueous methanol (HPLC grade;
Sigma-Aldrich, MO, USA) for the evaluation of monoamines, gluta-
mate and GABA. In the last set of experiments (n = 4 rats per sub-
groups), histological alterations in the striata of animals
representing each group were assessed.
2.3. Behavior and motor function
2.3.1. Open field test
Each rat was placed gently in the central area of the open-field
and allowed to freely explore the area for 3 min. Behavioral
changes, namely latency, rearing, ambulation, immobility time,
and grooming were recorded [27].
2.3.2. Rotarod test
Animals were placed in the orientation opposite to that of the
rotating rod (10 rpm). Before experimentation, rats were trained
for 3 days to remain on the stationary and rotating rod (3 sessions,
one min). Twenty-four hours after the last injection of rotenone,
animals were reevaluated for a period of 5 min and the fall off time
from the rod was recorded [28].Please cite this article in press as: N.F. Abdelkader et al., Pyrrolidine dithiocarb
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Striatal DA, noradrenaline and serotonin contents were esti-
mated according to the method of Pagel et al. [29]; using a fully
automated high pressure liquid chromatography system (HPLC;
Perkin-Elmer, MA, USA). Homogenates were spun at 4000g, for
20 min and supernatants were immediately extracted from trace
elements and lipids by the use of solid phase extraction CHROMA-
BOND column NH2 phase (Cat. No.730031; Macherey and Nagel,
Düren, Germany). Twenty ll of monoamine standards or samples
were injected directly into the AQUA column (150  4.6 mm 5 l
C18) from Phenomenex (CA, USA) and a mobile phase composed
of 97:3 mixture (v/v) of methanol: acetonitrile was used. A con-
stant flow rate of 1.5 ml/min was maintained throughout the
experiment that lasted for 12 min and the absorbance of monoami-
nes was measured at UV 270 nm.2.5. Striatal glutamate and GABA estimation
The amino acids were estimated using a fully automated HPLC
(Perkin-Elmer, MA, USA) according to the precolumn phenylisoth-
iocyanate derivatization technique described by Heinrikson and
Meredith [30]. For each sample, the supernatant was dried under
vacuum and the residues were reconstituted in 2:2:1 mixture (v/
v) of methanol, 1 M sodium acetate trihydrate, and triethylamine
then re-dried under vacuum. The reaction of derivatization was
performed for 20 min at room temperature using a 7:1:1:1 mixture
(v/v) of methanol, triethylamine, double distilled deionized water,
and phenylisothiocyanate, then subjected again to vacuum till dry-
ness. The derivatized amino acids were reconstituted with sample
diluent consisting of 5:95 mixture (v/v) of acetonitrile and 5 mM
phosphate buffer (pH = 7.2). After sonication, samples were filtered
through 0.45 l Millipore membrane. A Pico-Tag physiological free
amino acid analysis C18 (300 mm  3.9 mm i.d.) column from
Waters (MA, USA) and a binary gradient of Eluents 1 and 2
(Waters) were used. The column temperature was set at 46 ± 1 C
and a constant flow rate of 1 ml/min was maintained throughout
the experiment. Samples and standards were injected in volumes
of 20 ll and the absorbance of the derivatized amino acids was
measured at 254 nm.2.6. Striatal lipid peroxides estimation
The thiobarbituric acid reaction of Ruiz-Larrea et al. [31] was
adopted for estimation of lipid peroxides level, using malondialde-
hyde as a standard. Striatal homogenates were spun at 1000 xg for
20 min at 4 C. To supernatants, a working reagent of 0.8% (w/v)
thiobarbituric acid and 20% (w/v) trichloroacetic acid solutions
was added, mixtures were then heated for 20 min in a boiling
water bath, cooled and centrifuged at 1000g for 5 min. The absor-
bance of the pink colored product was read at 535 nm and
expressed as TBARS.2.7. Striatal GSH estimation
GSH was assessed using Ellman’s reagent as described by Beut-
ler et al. [32] Striatal homogenates were deproteinated with 5% (w/
v) 5-sulfuosalicylic acid for 30 min at 4 C and then centrifuged at
1000 xg for 15 min at 4 C. An aliquot of the acid soluble super-
natant was diluted with phosphate buffer (0.3 M, pH = 7.7), then
5,50 dithiobis-2-nitrobenzoic acid (1 mM) was added to the sam-
ples, and the optical density was determined at 412 nm.amate ameliorates rotenone-induced Parkinson’s disease in rats, Bulletin
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The method described by Bradley et al. [33] was employed to
determine MPO activity in striatal homogenate. MPO was
extracted from homogenates by freeze-thawing and sonication in
50 mM phosphate buffer (pH = 6) containing 0.5% (w/v) of hexade-
cyltrimethylammonium bromide, followed by centrifugation at
12,000g for 15 min at 4 C. Then, 0.167 mg/ml o-dianisidine
hydrochloride and 0.0005% (v/v) hydrogen peroxide in 50 mM
phosphate buffer (pH = 6) were added to an aliquot of the super-
natant. The absorbance rate at 460 nm was measured for 3 min
at room temperature.
2.9. Striatal TNF-a and caspase-3 estimations
Striatal TNF-a and caspase-3 contents were estimated using rat
TNF-a ELISA kit and caspase-3 colorimetric assay kit purchased
from Invitrogen (CA, USA) and R&D Systems (MN, USA), respec-
tively. Procedures were performed according to manufacturer’s
instructions.
2.10. Histological analysis of brain tissue
Brains were immediately fixed in 10% phosphate buffered
formaldehyde, subsequently embedded in paraffin, and 5 lm lon-
gitudinal sections were performed. The sections were stained with
haematoxylin and eosin (H&E) and examined microscopically.
2.11. Statistical analysis
Data were expressed as means ± S.E.M., and comparisons
between means were carried out using one-way ANOVA followed
by Tukey-Kramer multiple comparisons test. Non-parametric data
were analyzed using Kruskal-Wallis one-way ANOVA followed by
Dunn’s multiple comparisons test. A probability level of less thanFigure 1. Effect of pyrrolidine dithiocarbamate administration on behavioral activities o
control, @ p < 0.05 vs rotenone, using parametric One-Way ANOVA followed by Tukey-Kr
nonparametric One-Way ANOVA followed by Dunn’s multiple comparisons test for rear
Please cite this article in press as: N.F. Abdelkader et al., Pyrrolidine dithiocarb
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3. Results
Following rotenone administration, animals showed deteriora-
tion in their motor performance, reflected as hypokinesia and
impaired muscle coordination. Rotenone treated rats showed
decreased ambulation (17.9%; Fig. 1A), rearing (10.6%; Fig. 1B),
and grooming (12.9%; Fig. 1C) compared to the control animals.
Though the neurotoxicant did not alter akinesia (Fig. 1D), it
increased immobility time (301.2%; Fig. 1E) as compared to control
rats. Meanwhile, rotenone hampered muscle coordination as
observed by the reduced falling time on the rotating rod to 7.8%
(Fig. 1F) as compared to the control rats. These behavioral changes
were associated with decreased striatal DA levels (80.3%; Fig. 2A), a
cardinal mediator for motor activity, without affecting nora-
drenaline level (Fig. 2B). Such events were accompanied by striatal
neuronal hypoplasia and encephalomalacia (Fig. 3C) emphasizing
thus neuronal loss, as well as oedema (Fig. 3B). On the other hand,
daily administration of PDTC prevented the reduction in DA
induced by rotenone and enhanced its level by 145.3% (Fig. 2A)
above normal values, with no change in noradrenaline level
(Fig. 2B). In addition, PDTC treatment almost prevented all patho-
logical changes induced by rotenone in striatum affording thus
neuroprotection (Fig. 3D) along with improving motor coordina-
tion and locomotor activity (Fig. 1F). Indeed, PDTC increased falling
time of the rotating rod (42.7%; Fig. 1F), ambulation (68%; Fig. 1A),
and rearing (50.5%; Fig. 1B), while decreasing immobility time
(120.1%; Fig. 1E) in the open field compared to normal rats.
Rotenone reduced also striatal glutamate content (83%; Fig. 4A)
that was further suppressed by the antioxidant PDTC (64.6%) with
respect to the control values. On the other hand, rotenone raised
striatal contents of both GABA (125.7%; Fig. 4B) and serotonin
(228.1%; Fig. 4C) that were unaffected by PDTC treatment. More-f parkinsonian rats. Data are expressed as mean ± S.E.M of 8–9 animals; ⁄p < 0.05 vs
amer multiple comparisons test for latency, immobility, and falling time, as well as
ing, ambulation, and grooming.
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Figure 2. Effect of pyrrolidine dithiocarbamate administration on striatal dopamine
and noradrenaline contents in parkinsonian rats. Data are expressed as mean ± S.E.
M of 8 animals; ⁄p < 0.05 vs control, @ p < 0.05 vs rotenone, using One-Way ANOVA
followed by Tukey-Kramer multiple comparisons test.
Figure 3. Photomicrographs for striatal sections of A) control, B & C) rotenone and D) P
cellular hypoplasia and encephalomalacia (arrow) (C). PDTC treatment protects dopamine
rotenone group (H & E X 40).
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Fig. 5A) and myeloperoxidase (MPO; 364%; Fig. 5B) that were par-
tially suppressed by PDTC (161.5 and 264%, respectively), com-
pared to their control animals. In addition, the elevated GSH
content (169%; Fig. 5C) by rotenone was also restored by PDTC
treatment. Neither striatal caspase-3 nor TNF-a contents (Table 1)
were altered by the insult; however, the pro-inflammatory cyto-
kine was lowered (66.7%) by PDTC treatment.
4. Discussion
The novel findings of the current study reveal that PDTC pro-
tected the striatum against neurotoxic effects of rotenone in rats.
Neuroprotection is based on the noted microscopical and motor
improvements after PDTC treatment. These findings are advocated
to the spike in striatal DA, the core player in PD pathogenesis, and
the reduction in oxidative stress and microglial activation in the
striatum. However, serotonin, GABA and glutamate play negligible
roles in neuroprotection afforded by PDTC in the present work.
Oxidative stress plays a pivotal role in neuronal death in PD
induced by rotenone [24]; that was observed as neuronal hypopla-
sia of the striatum in the current work. In this study, rotenone
exposure produces an imbalance in the striatal redox status evi-
dent by the elevation in both the antioxidant GSH and TBARS, sig-
nifying free radical production. The enhanced level of lipid
peroxides in the striatum is in line with previous studies [25,34].
Interestingly, a raise of striatal thiol content was observed after
rotenone treatment, an effect that could be explained by the upreg-
ulation of GSH in response to low doses of the insult to guard
against augmented levels of free radicals. Indeed, an in vitro study
conducted by Seyfried et al. [35] showed that treatment with low
concentrations of rotenone increased cellular GSH.
Among sources of free radicals are the microglia, mitochondria,
and DA oxidation [36–38]. In fact, Chang et al. [39] reported that
MPO activity was elevated in microglia after rotenone treatment
and was shown to be increased in the present work. In the currentDTC-treated rats. Rotenone group shows dispersing oedema (arrow) (B) as well as
rgic neurons (D), as evidenced by almost normalization of the striatum compared to
amate ameliorates rotenone-induced Parkinson’s disease in rats, Bulletin
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Figure 4. Effect of pyrrolidine dithiocarbamate administration on striatal glutamate, GABA and serotonin contents in parkinsonian rats. Data are expressed as mean ± S.E.M of
8 animals; ⁄p < 0.05 vs control, @ p < 0.05 vs rotenone, using One-Way ANOVA followed by Tukey-Kramer multiple comparisons test.
Figure 5. Effect of pyrrolidine dithiocarbamate administration on striatal TBARS and GSH contents and activity of MPO in parkinsonian rats. Data are expressed as mean ± S.E.
M of 6–9 animals; ⁄p < 0.05 vs control, @ p < 0.05 vs rotenone, using One-Way ANOVA followed by Tukey-Kramer multiple comparisons test.
Table 1
Effect of pyrrolidine dithiocarbamate administration on striatal TNF-a content and
caspase-3 activity in parkinsonian rats.
Groups TNF-a Caspase-3
(pg/g tissue) (Fold change)
Control 254.00 ± 20.29 1
Rotenone 230.71 ± 15.92 1.057 ± 0.071
PDTC 169.45 ± 9.53*@ 1.030 ± 0.158
Data are expressed as mean ± S.E.M of 6–9 animals.
* p < 0.05 vs control.
@ p < 0.05 vs rotenone, using One-Way ANOVA followed by Tukey-Kramer mul-
tiple comparisons test.
N.F. Abdelkader et al. / Bulletin of Faculty of Pharmacy, Cairo University xxx (2016) xxx–xxx 5investigation, PDTC effectively reduced both lipid peroxides and
MPO. These data are in agreement with previous studies showing
that PDTC successfully decreased lipid peroxidation and MPO
activity in paraquat treated rats [15,40]. By virtue of its dithiocar-
boxy functional group, PDTC scavenges hypochlorous acid, a strong
oxidant released fromMPO and chelates heavy metal ions that cat-
alyze ROS formation, thus hampering free radicals generation
[23,41]. Moreover, PDTC upregulates the expression of endogenous
antioxidants [15], hence increasing cellular antioxidants defenses
that intercept the free radical vicious cycle. These events might
thus dampen lipid peroxides formation and normalize GSH level,
as documented in this investigation.
Apart from the direct free radical generation by virtue of its
prominent complex-I inhibition, rotenone impairs ATP production
disturbing the ionic gradient essential for the DA vesicular uptake
[36,42]. The latter effect is accompanied by depolymerization of
microtubules disrupting vesicular transport along microtubules
by rotenone [43]. These events lead to extra release of DA in or
near DAergic neurons to be metabolized in the extracellular milieu,Please cite this article in press as: N.F. Abdelkader et al., Pyrrolidine dithiocarb
Facult Pharmacy Cairo Univ (2016), http://dx.doi.org/10.1016/j.bfopcu.2016.11where DA oxidation produces free radicals that damage DAergic
neurons [43]. Hence, the reduction in DA level produced by rote-
none exposure without change in noradrenaline level, in the cur-
rent work, points to its enhanced turn over that is associated by
ROS production evidenced in the present work by elevated TBARS
and GSH levels. Surprisingly, PDTC elevated DA above normal
levels in the present work. Such an action might be ascribed to
preservation of DAergic neurons, as documented by histopatholog-
ical findings of the current work, besides de novo synthesis of DA
and/or the reduction in its catabolism as empathized by Cvek
and Dvorak [44]. These authors reported that disulfiram, another
dithiocarbamate, inhibits dopamine-b-hydroxylase. Therefore,
PDTC via hindering neuronal hypoplasia evoked by rotenone in
the striatum and elevating DA level could ease behavioral deficits
associated by rotenone exposure in this study. Neuroprotection
afforded by PDTC is in line with the previous work of Chauhan
et al. [45] which showed that pre-treatment with PDTC amelio-
rated behavioral and neurodegenerative indices in Zn-induced PD
in rats.
Beside decreased glutamate release, as previously reported by
Meshul et al. [46] in 6-hydroxydopamine-lesioned rats, the present
work shows a reduction in glutamate striatal content after
subchronic rotenone exposure. Unexpectedly, the current study
displays that PDTC further reduced glutamate level in the striatum.
Leng et al. [47] presented that the neuroprotective effect of
a-phenyl-tert-butyl nitrone is independent on alterations in
glutamate, concluding thus its insignificant role in the neuronal
preservation by this agent. The current study supports these data
pointing thus to the negligible role of this neurotransmitter in
the observed neuroprotection afforded by PDTC in the current
work. Furthermore, the present investigation revealed a rise in
serotonin content after rotenone treatment, which is not affectedamate ameliorates rotenone-induced Parkinson’s disease in rats, Bulletin
.003
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tonin content in SN after intranigral infusion of rotenone in rats, an
effect that resides in serotonergic system stimulation [49]. Fukuda
et al. [50] and Rozas et al. [51] explained that in MPTP model
increased serotonin synthesis and/or induced sprouting of seroton-
ergic axons occur. Since PDTC failed to reduce the elevated sero-
tonin level induced by rotenone, hence it does not affect
seretonin, pointing to the minor involvement of this monoamine
in the antioxidant’s antiparkinsonian action.
Though augmented TNF-a level has been correlated with apop-
tosis of DAergic neurons [52], in the current work, rotenone neither
affected TNF-a nor caspase-3, pointing to the fact that neuronal
death is not mediated by apoptosis. Though, these data are in line
with previous studies [53,54], in other reports that used higher
dose and longer rotenone regimens both biomarkers were elevated
[55,56]. Notably, in the present work, PDTC decreased TNF-a below
baseline, an effect corroborating another experimental model and
could be attributed to transcriptional inhibition of the pro-
inflammatory cytokine [57].
5. Conclusion
In conclusion, the current study demonstrates that PDTC
potently reduces neuronal damage and its associated motor
impairment in experimentally-induced PD-like model. The
antiparkinsonian effect is attributable to PDTC profound enhance-
ment of DA, as well as its antioxidant and anti-inflammatory
properties.
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